Open Access

In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin

  • Authors:
    • Sayaka Tsukioka
    • Etsuko Sakamoto
    • Hiroaki Tsujimoto
    • Fumio Nakagawa
    • Hitoshi Saito
    • Junji Uchida
    • Mamoru Kiniwa
    • Masakazu Fukushima
  • View Affiliations

  • Published online on: March 4, 2011     https://doi.org/10.3892/or.2011.1206
  • Pages: 1407-1412
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Combined chemotherapy with 5-fluorouracil and leucovorin (LV) has been widely used for the treatment of patients with colorectal cancer. Given that LV effects are attributable to increased levels of reduced folate in cancer cells, we attempted here to show the in vivo role of folylpolyglutamate synthetase (FPGS), which stabilizes intracellular reduced folate, in the anticancer activities of oral fluoropyrimidines, UFT or S-1, combined with LV. To this end, HCT-15 human colon cancer cells were knocked down for FPGS expression by RNA interference. The cell line stably expressing FPGS shRNA (FPGS shRNA HCT-15) was cloned and transferred subcutaneously into nude mice fed a low-folate diet. FPGS shRNA HCT-15 tumors expressed a significantly lower level of FPGS at protein and mRNA levels than parental HCT-15 cells, and the levels of reduced folate in FPGS shRNA HCT-15 tumors became 57% of those in parent after a single administration of 10 mg/kg of LV. Notably, FPGS downregulation did not affect the tumor growth or sensitivity to fluoropyrimidine. Importantly, we observed that LV given for 14 days failed to enhance the anticancer effects of UFT and S-1 in FPGS shRNA HCT-15. This was in keeping with the results that LV did not increase the ternary complex of TS, FdUMP and reduced folate. In conclusion, the present results provide in vivo evidence that intratumor FPGS plays an important role in the efficacy of oral fluoropyrimidine plus LV therapy for colorectal cancer.

Related Articles

Journal Cover

May 2011
Volume 25 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tsukioka S, Sakamoto E, Tsujimoto H, Nakagawa F, Saito H, Uchida J, Kiniwa M and Fukushima M: In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin. Oncol Rep 25: 1407-1412, 2011.
APA
Tsukioka, S., Sakamoto, E., Tsujimoto, H., Nakagawa, F., Saito, H., Uchida, J. ... Fukushima, M. (2011). In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin. Oncology Reports, 25, 1407-1412. https://doi.org/10.3892/or.2011.1206
MLA
Tsukioka, S., Sakamoto, E., Tsujimoto, H., Nakagawa, F., Saito, H., Uchida, J., Kiniwa, M., Fukushima, M."In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin". Oncology Reports 25.5 (2011): 1407-1412.
Chicago
Tsukioka, S., Sakamoto, E., Tsujimoto, H., Nakagawa, F., Saito, H., Uchida, J., Kiniwa, M., Fukushima, M."In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin". Oncology Reports 25, no. 5 (2011): 1407-1412. https://doi.org/10.3892/or.2011.1206